Evolocumab + Atorvastatin
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes, Hyperlipidemia, Mixed Dyslipidemia
Conditions
Diabetes, Hyperlipidemia, Mixed Dyslipidemia
Trial Timeline
Apr 14, 2016 → Dec 6, 2017
NCT ID
NCT02662569About Evolocumab + Atorvastatin
Evolocumab + Atorvastatin is a phase 3 stage product being developed by Amgen for Diabetes, Hyperlipidemia, Mixed Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02662569. Target conditions include Diabetes, Hyperlipidemia, Mixed Dyslipidemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02662569 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetes, Hyperlipidemia, Mixed Dyslipidemia